IGNOU MSTE 3 SOLVED ASSIGNMENT

Included:

MSTE 3 2025 - English

TUTOR MARKED ASSIGNMENT

MSTE-003: Biostatistics-I

Assignment Code: MSTE-003/TMA/2022

Course Code: MSTE-003

Maximum Marks: 100

Note: All questions are compulsory. Answer in your own words.

1. State whether the following statements are True or False. Give reason in support of your answer:

(a) Suppose A is the exposure and B is a confounding factor for outcome C, then there will be a path from A to C via B.

(b) Doing exercise may also be a regimen.

(c) In clinical trials, a control only may be: treatment or no treatment.

(d) In Greville’s method, the central death rate is more in the life table than the population.

(e) In a slope ratio assay, both regression lines have common slope.

2. Explain with examples:

(a) Various sources of demographic data in India

(b) Types of bioassays

(c) LD50 and ED50

3. (a) Differentiate between complete and abridged life tables.

(b) The data on population and number of deaths for different age groups of Districts A and B in the year 2001 were collected in the following table:

same data in tabular form:

Age Group (Years)	District A		District B
	Population	No. of Deaths	Population	No. of Deaths
0 - 5	55,300	385	51,165	805
5 - 15	109,125	410	98,170	510
15 - 35	1,72,050	675	1,68,450	790
35 - 50	1,15,600	1625	1,40,625	990
50 & above	2,65,775	3288	2,40,900	2485

Calculate standardised death rate by direct method, taking population of District A as the standard population.

4. In a parallel-line assay, total 18 guinea pigs, 4 guinea pigs each from 3 different breeds were selected and classified into 4 groups for each breed. Two groups were administered with two doses of the standard preparation and remaining two groups with two doses of the test preparation. The responses of these doses are recorded in the following table:

ular form:

	Dose (Standard)			Dose (Test)
Breed	10 (in µL)	15 (in µL)	20 (in µL)	5 (in µL)	10 (in µL)	15 (in µL)
1	25	42	55	20	43	64
2	23	47	52	23	42	66
3	22	38	58	24	44	67

(i) Determine the dose-response regression models for both preparations.

(ii) Test whether the dose-response curves of both preparations are linear and parallel to each other or not.

(iii) Interpret whether the relative potency and its confidence interval can be computed or not.

5(a) If D+ and D ̶ denote presence and absence, respectively, of a disease and T+ and T ̶ denote test result as positive and negative, respectively, then on the basis of the following information:

	D⁺	D⁻	Total
T⁺	145	2000	2145
T⁻	15	48000	48015
Total	160	50000	50160

Find: (i) sensitivity (ii) specificity (iii) positive and negative predictive values.

(b) Obtain sample size for the following given information:

0.04,0.72,0.84,0.010.25

6.(a) Explain design and analysis of data of case control study in detail.

(b) Creatinine excretion isa parameter of kidney function. Generally speaking, lower values indicate better health. This depends on body weight. A researcher conducted a study on creatinine excretion in test group and control group to find the efficacy of a new drug. The subjects were randomly divided. He included 100 subjects in each group but for this exercise consider only 10 subjects in each group. The data obtained on creatinine level in these 10 subjects are as follows:

Test Group	16.6	19.8	17.1	17.0	15.6	20.3	24.7	18.5	17.6	22.0
Control Group	23.2	22.0	21.9	16.7	14.2	23.2	24.8	25.5	28.1	21.8

Do you think that creatinine excretion was really lower in the test group on average?

7. Suppose you try a regimen A on 1000 subjects and regimen B on 1600 subjects. Results of the trial show that efficacies of regimen A and B are 76% and 82% respectively. Suppose doctor determines 4% as superiority margin. Can you consider regimen B as superior to regimen A.

 

MSTE 003 (January 2026 - July 2026) - ENGLISH

TUTOR MARKED ASSIGNMENT

MSTE-003: Biostatistics-I

Course code: MSTE-003

Assignment Code: MSTE-003/TMA/2026

Maximum Marks: 100

Note: All questions are compulsory. Answer in your own words.

1. State whether the following statements are True or False. Give reason in support of your answer:

(a) Equality of slopes is the basic requirement for the parallel-line assay.

(b) The quantal assay is applicable when the response is the percentage of subjects who responded to a treatment at different doses.

(c) A complete life table is more elaborate than an abridged life table.

(d) Primary prevention includes strategies designed to reduce the incidence of disease.

(e) In Phase II of a clinical trial, we determine a safe dosage range and identify potential side effects.

2. In a quantal assay, the number of cured cases for five doses of a standard and four doses of a new test drug are recorded in the following table:

	$mathbf{d_i}$	$mathbf{n_i}$	$mathbf{r_i}$
Standard	3	28	4
	6	30	8
	9	24	12
	12	32	22
	15	27	21
Test	2	31	3
	4	25	9
	6	30	16
	8	25	16

Determine the median effective dose for the standard and test drugs using regression model.

3(a). Write a short note on the Sampling Registration method of data collection for vital statistics.

(b) The number of births occurring in a country in 2015 classified according to age of mother, together with the female population in each group of the childbearing period, is given as follows:

Age	Female Population (in '000)	Number of Births to the mother in the age group
15 - 19	84.79	2,343
20 - 24	70.01	14,541
25 - 29	72.66	16,736
30 - 34	75.92	10,218
35 - 39	75.10	5,134
40 - 44	71.62	1,422
45 - 49	66.66	93
Total	516.66	50,487

The total population of the country in 2015 was 2285.8 thousand. Using the given information, determine the following:

(i) CBR,

(ii) GFR,

(iii) ASFR for the country in 1958.

4(a). In a hypothetical study, 10 patients with kidney disease were randomly assigned to receive two dialysis methods (A and B). 5 patients received Dialysis-A followed by Dialysis-B, and the remaining 5 received Dialysis-B followed by Dialysis-A. The kidney function scores of these patients are given as:

	Group-I (AB Sequence)
Patient No.	1	2	3	4	5
Dialysis-A	69	73	50	69	76
Dialysis-B	68	79	68	72	85

 

	Group-II (BA Sequence)
Patient No.	6	7	8	9	10
Dialysis-B	57	70	75	70	69
Dialysis-A	51	71	53	62	64

Test whether the mean score for dialysis-A is different from the mean score of dialysis-B, assuming no carry-over effect.

(b) Describe descriptive and analytic epidemiology.

5(a). Explain any five types of biases in clinical trials.

(b) Differentiate between direct and indirect bioassays.

(c) Explain the steps taken for minimising bias in a research setup of a clinical trial.

(d) Define experimental and non-experimental studies.

 

Q: How will I receive the PDF?
A: Immediately after payment, the download link will appear and be sent to your email.

Q: Is this hand-written or typed?
A: This is a professional typed computer PDF. You can use it as a reference for your handwritten submission.